News | Antiplatelet and Anticoagulation Therapies | April 15, 2019

Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance

Despite national guidelines indicating that statins can lower risk of heart attack and stroke, many patients who could benefit do not take them

Lack of Physician Guidance, Fear of Side Effects Influence Statin Compliance

April 15, 2019 — Despite national guidelines indicating statins can lower risk of heart attack and stroke, many patients who could benefit do not take them. More than half of eligible patients say they were never offered the cholesterol-lowering drugs; the experience of side effects or fear of side effects were reasons for stopping or refusing statins, according to new research in Journal of the American Heart Association.1

Statins lower the amount of low-density lipoprotein (LDL, or “bad” cholesterol), and have been shown to lower the risk of heart attack and strokes. Because statins are proven effective and have a low risk of side effects, guidelines from the American Heart Association/American College of Cardiology recommend doctors use an atherosclerotic and cardiovascular disease risk calculator to give a detailed assessment of a person's 10-year risk for heart disease and to help create a personalized plan.

“We need to focus our efforts on improving how doctors identify patients who need to be on a statin, and how they present information to patients to ensure that no one is missing the opportunity to improve their heart health,” said Corey Bradley, M.D., lead author of the study and a researcher at the Duke Clinical Research Institute in Durham, N.C.

To find out whether eligible patients use statins, and why they sometimes decline or discontinue the drugs, researchers surveyed 5,693 adults (average age 68) who participated in a registry for those receiving medical care at a cardiology, primary care or endocrinology practice.

Researchers found:

  • Of the 1,511 (26.5 percent) who were not currently taking statins, 59.2 percent reported that they had never been offered them;
  • Patients were more likely to report never being offered a statin if they were female (22 percent higher than others), black (48 percent higher than others), or without insurance (38 percent higher than others); and
  • Patients seen in cardiology practices were more likely to be offered a statin than those in primary care.

“It is possible that some people did not remember being offered a statin, so we may have overestimated the percent who were never offered one. However, we believe that if the patient did not remember the conversation, the discussion likely was not an effective one,” Bradley said.

Of the patients who declined (10.1 percent) or discontinued (30.7 percent) statins, the most common reasons given were a fear of side effects and perceived side effects. Compared with statin users, non-users were less likely to believe statins are safe.

“Although there are risks associated with statins, the public fear of side effects is out of proportion to the actual risks,” said Ann Marie Navar, M.D., Ph.D., senior author of the study and assistant professor of Medicine at the Duke Clinical Research Institute. “Misconceptions about statins are everywhere and are fueled by false information on the internet. We need better tools to help combat this type of misinformation.”

Despite their concerns, in the survey 59.7 percent of patients who discontinued a statin would consider retrying it.

“Physicians should not hesitate to reapproach the conversation about starting or retrying statin therapy in patients who could benefit but are currently not on the therapy,” Bradley said.

For more information: www.ahajournals.org/journal/jaha

Reference

1. Bradley C.K., Wang T.Y., Li S., et al. Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry. Journal of the American Heart Association, March 27, 2019. https://doi.org/10.1161/JAHA.118.011765

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...